ALERTS & COVID-19 UPDATES Learn more: COVID-19 Resources; COVID-19 Testing; Vaccine Info; Visitor Policy; Support Us

[LCID Study Number: 20193097]

Alliance A031702, A phase II study of Ipilimumab, CabOzantinib, and NIvolumab in rare genitourinary Cancers (ICONIC)

This study is being done to test the good and bad effects of the drugs called cabozantinib, nivolumab and ipilimumab, when given in combination. This combination of drugs may or may not shrink your cancer, but it could also cause side effects. The study doctors hope to learn if the study drugs will stabilize or shrink your cancer.

Primary Contact Email: [email protected]

Primary Contact Phone: 781-744-3421